| 1 | Prolonged release pirfenidone pharmacokinetics is modified in cirrhosis GENESIS study | 1ᵉʳ autor: Poo, Jorge L., Aguilar, Juan R., Bernal-Reyes, Raul, Alonso-Campero, Rosalba, et al. | 2023 | BIOMEDICINE & PHARMACOTHERAPY | WoS-id: 001093163400001
Scopus-id: 2-s2.0-85174712739
| 0 | 0 |
| 2 | PROLONGED- RELEASE PIRFENIDONE IN PATIENTS WITH COMPENSATED CIRRHOSIS. FINAL RESULTS OF THE MULTICENTER STUDY ODISEA, CONTROLLED AGAINST PLACEBO, PLUS STANDARDIZED CARE | Coautor: Poo, JL, Munoz-Espinosa, LE, Torre, A, Cisneros, L, et al. | 2023 | Hepatology | WoS-id: 001094865403428
| 0 | 0 |
| 3 | Benefits of prolonged-release pirfenidone plus standard of care treatment in patients with advanced liver fibrosis: PROMETEO study | 1ᵉʳ autor: Poo J.L., Torre A., Aguilar-Ramírez J.R., Cruz M., et al. | 2020 | HEPATOLOGY INTERNATIONAL | WoS-id: 000561005700001
Scopus-id: 2-s2.0-85089585427
| 32 | 35 |
| 4 | The Mexican consensus on nonalcoholic fatty liver disease | Coautor: Poo-Ramírez J.L., Bernal-Reyes R., Castro-Narro G., Malé-Velázquez R., et al. | 2019 | REVISTA DE GASTROENTEROLOGIA DE MEXICO | WoS-id: 000458659700009
Scopus-id: 2-s2.0-85060727346
| 36 | 40 |
| 5 | The Mexican consensus on the treatment of hepatitis C | Coautor: Poo-Ramírez J.L., Aiza-Haddad I., Ballesteros-Amozurrutia A., Borjas-Almaguer O.D., et al. | 2018 | REVISTA DE GASTROENTEROLOGIA DE MEXICO | Scopus-id: 2-s2.0-85047343054
| 0 | 9 |
